Allogene Therapeutics (ALLO): 10 Best Growth Stocks Under $10 to Invest In [Yahoo! Finance]
Allogene Therapeutics, Inc. (ALLO)
Last allogene therapeutics, inc. earnings: 2/27 04:30 am
Check Earnings Report
Company Research
Source: Yahoo! Finance
regulatory clearance to expand its pivotal Phase 2 ALPHA3 study of cemacabtagene ansegedleucel (cema-cel) into South Korea and Australia. This expansion increases the trial's global footprint to over 80 sites, up from the current 60 in North America, with patient screening and enrollment in these new regions expected to begin in Q2 2026. The study evaluates cema-cel as a first-line consolidation treatment for patients with large B-cell lymphoma/LBCL who show minimal residual disease/MRD after initial chemotherapy. The decision to expand follows positive interim futility analysis data from the first 24 patients, which showed that cema-cel achieved a 58.3% MRD clearance rate compared to just 16.7% in the standard-of-care observation group. Additionally, the therapy was well-tolerated with no reported cases of cytokine release syndrome or neurotoxicity. Allogene Therapeutics (ALLO): 10 Best Growth Stocks Under $10 to Invest In Allogene Therapeutics Inc. (NASDAQ:ALLO) aims to enroll
Show less
Read more
Impact Snapshot
Event Time:
ALLO
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
ALLO alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
ALLO alerts
High impacting Allogene Therapeutics, Inc. news events
Weekly update
A roundup of the hottest topics
ALLO
News
- H.C. Wainwright Maintains Buy Rating on Allogene Therapeutics (ALLO) [Yahoo! Finance]Yahoo! Finance
- Allogene Therapeutics Expands Pivotal Phase 2 ALPHA3 Trial to South Korea and AustraliaGlobeNewswire
- Allogene Therapeutics Showcases Momentum with Clinical and Platform Advancements in Allogeneic CAR T at AACR 2026GlobeNewswire
- Allogene Therapeutics Announces Closing of $200.4 Million Public Offering of Common StockGlobeNewswire
- Allogene Therapeutics (ALLO) was upgraded by JPMorgan Chase & Co. from "underweight" to "neutral".MarketBeat
ALLO
Earnings
- 3/12/26 - Beat
ALLO
Sec Filings
- 4/23/26 - Form 4
- 4/23/26 - Form SCHEDULE
- 4/21/26 - Form 144
- ALLO's page on the SEC website